Advanced Solid Tumor Clinical Trials in Houston, Texas

54 studies are recruiting for advanced solid tumor in Houston, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies, page 2

1. A Study of MGC026 in Participants With Advanced Solid Tumors

   The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort ex…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   12 in total

   Run by

   MacroGenics

   See if you can join NCT06242470 on ClinicalTrials.gov

2. SLV-154 Treatment of Advanced Cancers

   This is a Phase 1 study comprising a Phase 1a dose-escalation portion and a Phase 1b expansion portion evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-154 across a range of dose levels when administered to subjects with advanced solid tumors.

   Stage

   Phase 1

   Ages

   12 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Locations

   10 in total

   Run by

   Solve Therapeutics

   See if you can join NCT06771219 on ClinicalTrials.gov

3. Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

   This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-341 administered orally as a single agent or combination therapy in patients w…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Investigative Site #129, Houston, Texas

   Locations

   15 in total

   Run by

   MOMA Therapeutics

   See if you can join NCT06974110 on ClinicalTrials.gov

4. Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

   This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a randomized study of STK-012 in combination with standard of…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Oncology Consultants, Houston, Texas

   Locations

   47 in total

   Run by

   Synthekine

   See if you can join NCT05098132 on ClinicalTrials.gov

5. A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

   This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are either direct (YES1 amplification) or dependent (Hippo Pathway altera…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   15 in total

   Run by

   Nuvectis Pharma, Inc.

   See if you can join NCT05873686 on ClinicalTrials.gov

6. A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors

   The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C137 alone and in combination with anticancer agents in participants with advanced solid tumors. The study will be conducted in two phases: Phase 1a (…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Md Anderson Cancer Center, Houston, Texas

   Locations

   52 in total

   Run by

   BeOne Medicines

   See if you can join NCT06625593 on ClinicalTrials.gov

7. A Study of PYX-201 in Advanced Solid Tumors

   The primary objectives of this study are to determine the recommended dose(s) of PYX-201 for participants with recurrent/metastatic (R/M) solid tumors, and to determine the objective response rate (ORR) in participants treated with PYX-201 as a single agent.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   29 in total

   Run by

   Pyxis Oncology, Inc

   See if you can join NCT05720117 on ClinicalTrials.gov

8. SNV1521 in Participants With Advanced Solid Tumors

   This study is testing a new medicine, SNV1521, for people with advanced cancers. The researchers want to find out if SNV1521 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the most effective and safe one. They are also invest…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Texas M.D. Anderson Cancer Center, Houston, Texas

   Locations

   25 in total

   Run by

   Synnovation Therapeutics, Inc.

   See if you can join NCT06220864 on ClinicalTrials.gov

9. Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors

   This is a Phase I/II open label study of intravenous (IV) infusion of ONC-841 as a single agent or in combination in patients with advanced/metastatic solid tumors. The study will evaluate seven dose levels of ONC-841. The Phase 1 part is dose escalation with 7 dose levels of ONC-841 and the dose e…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Locations

   8 in total

   Run by

   OncoC4, Inc.

   See if you can join NCT06352359 on ClinicalTrials.gov

10. A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors

    This study consists of a Dose-Escalation stage and a Dose Expansion stage. The primary purpose of the dose escalation stage is to determine the maximum tolerated dose (MTD) and/or recommended dosage(s) for expansion (RDE[s]); and the dose expansion stage is to evaluate the preliminary antitumor act…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Exelixis Clinical Site #9, Houston, Texas

    Locations

    11 in total

    Run by

    Exelixis

    See if you can join NCT06952010 on ClinicalTrials.gov

11. A Study of YL201 in Patients With Advanced Solid Tumors

    This is a phase 1, multicenter, nonrandomized, open-label, first-in-human study of YL201 conducted in China and the United States. The study will include 2 parts: a dose escalation part (Part 1) followed by a dose expansion part (Part 2). Part 1 will estimate the MTD/RED(s) in dose escalation cohor…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    014, Houston, Texas

    Locations

    45 in total

    Run by

    MediLink Therapeutics (Suzhou) Co., Ltd.

    See if you can join NCT05434234 on ClinicalTrials.gov

12. BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

    This study is a multiple cohort, multicenter, open-label Phase 1 study with dose-escalation substudies investigating intravenous (IV) BAL0891 as monotherapy, and in combination with tislelizumab or paclitaxel, to determine the safety and tolerability of increasing doses of BAL0891 in patients with …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Texas MD Anderson Cancer Center, Houston, Texas

    Locations

    17 in total

    Run by

    SillaJen, Inc.

    See if you can join NCT05768932 on ClinicalTrials.gov

13. Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

    This is a single group study of participants with advanced solid tumors who have not been cured by other treatments. It is the first time the drug will be used in humans, and will be in two parts. The primary purpose of the parts are: * Dose Escalation Part: To evaluate the safety and tolerability …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MDACC (MD Anderson Cancer Center), Houston, Texas

    Locations

    28 in total

    Run by

    Daiichi Sankyo

    See if you can join NCT04145622 on ClinicalTrials.gov

14. Study in Advanced Solid Tumor Patients

    The study will be conducted in 2 phases: Phase 1: Dose-escalation and Dose Level Expansion, Phase 1 will determine the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE). Phase 2: Tumor-Specific Expansions with Dose Optimization, Phase 2 will further evaluate CLIO-8221 in tumo…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Locations

    11 in total

    Run by

    Callio Therapeutics

    See if you can join NCT07300943 on ClinicalTrials.gov

15. A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

    This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens. Currently study will only be enrolling the Phase 1b and the Phase 2a protocol requirements will be added to the study nea…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Locations

    5 in total

    Run by

    7 Hills Pharma, LLC

    See if you can join NCT06362369 on ClinicalTrials.gov

16. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

    Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Locations

    21 in total

    Run by

    Clasp Therapeutics, Inc.

    See if you can join NCT06778863 on ClinicalTrials.gov

17. A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors

    This is a 3-part study. Phase 1a (dose escalation) is designed to assess the safety and tolerability and to determine the maximum tolerated dose (MTD) and putative recommended phase 2 dose (RP2D) of study drug as monotherapy. Phase 1b (Cohort Expansion) is intended to further characterize the safet…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Texas MD Anderson Cancer Center, Houston, Texas

    Locations

    6 in total

    Run by

    OBI Pharma, Inc

    See if you can join NCT07124117 on ClinicalTrials.gov

18. A Study of YL242 in Subjects With Advanced Solid Tumors

    This is a multicenter, open-label study to evaluate the safety and tolerability of YL242 monotherapy and combination in participants with advanced solid malignant tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    US-203, Houston, Texas

    Locations

    15 in total

    Run by

    MediLink Therapeutics (Suzhou) Co., Ltd.

    See if you can join NCT07197827 on ClinicalTrials.gov

19. JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors

    This Phase 1 first-in-human study will investigate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of JZP898 monotherapy as well as JZP898 in combination with pembrolizumab in adult participants with advanced or metastatic solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Texas MD Anderson Cancer Center, Houston, Texas

    Locations

    10 in total

    Run by

    Jazz Pharmaceuticals

    See if you can join NCT06108050 on ClinicalTrials.gov

20. FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

    This is a phase 1 study designed to evaluate the safety, tolerability, and antitumor activity of FT825 (also known as ONO-8250) with or without monoclonal antibody therapy following chemotherapy in participants with advanced human epidermal growth factor receptor 2 (HER2)-positive or other advanced…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Texas MD Anderson Cancer Center, Houston, Texas

    Locations

    14 in total

    Run by

    Fate Therapeutics

    See if you can join NCT06241456 on ClinicalTrials.gov

21. A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

    This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    M.D. Anderson Cancer Center, Houston, Texas

    Locations

    14 in total

    Run by

    Volastra Therapeutics, Inc.

    See if you can join NCT05902988 on ClinicalTrials.gov

22. Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

    Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-001 Delivered by Intratumoral Injection in Patients with Advanced Solid Tumors as a Monotherapy or in Combination with Pembrolizumab. The study no…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Texas MD Anderson Cancer Center, Houston, Texas

    Locations

    7 in total

    Run by

    Strand Therapeutics Inc.

    See if you can join NCT06249048 on ClinicalTrials.gov

23. A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

    This is a first-in-human (FIH), multicenter, open-label Phase I study to investigate the safety, tolerability, preliminary antitumor activity, as well as pharmacokinetics (PK) and pharmacodynamics of XL309 (previously ISM3091) administered alone or in combination with olaparib in participants with …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Exelixis Clinical Site #1, Houston, Texas

    Locations

    16 in total

    Run by

    Exelixis

    See if you can join NCT05932862 on ClinicalTrials.gov

24. A Beta-only IL-2 ImmunoTherapY Study

    This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Locations

    27 in total

    Run by

    Medicenna Therapeutics, Inc.

    See if you can join NCT05086692 on ClinicalTrials.gov

25. A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer

    This is a Phase 1, open-label, dose escalation study to assess the safety, tolerability, and preliminary efficacy of SOT201 as monotherapy for participants aged 18 years or above with advanced unresectable or metastatic solid tumors During dose escalation, the recommended dose(s) of SOT201 given ev…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Locations

    7 in total

    Run by

    SOTIO Biotech AG

    See if you can join NCT06163391 on ClinicalTrials.gov